Literature DB >> 30548064

Antisense Oligonucleotide-Conjugated Nanostructure-Targeting lncRNA MALAT1 Inhibits Cancer Metastasis.

Ningqiang Gong1,2,3,4, Xucong Teng1, Jinghong Li1, Xing-Jie Liang2,3,4.   

Abstract

Metastasis-associated lung adenocarcinoma transcript 1 (MALAT1), a long noncoding RNA (lncRNA) located in the cell nucleus, is a critical regulator of tumor cell migration. Antisense oligonucleotides (ASOs), which can downregulate the expression level of specific RNAs, have been used in clinical for disease treatment. Herein, we constructed MALAT1-specific ASO and nucleus-targeting TAT peptide cofunctionalized Au nanoparticles, namely, ASO-Au-TAT NPs, which stabilized the fragile ASOs, enhanced nuclear internalization, and exhibited good biocompatibility. After treatment with the ASO-Au-TAT NPs, A549 lung cancer cells showed a greatly reduced MALAT1 expression level and decreased migration ability  in vitro. Moreover, the ASO-Au-TAT NPs significantly reduced metastatic tumor nodule formation in vivo. Our results demonstrate that the ASO-Au-TAT nanostructures (NSs) have great potential for treatment of cancer metastasis.

Entities:  

Keywords:  MALAT1; cancer metastasis; gene therapy; long noncoding RNA; nanostructure

Mesh:

Substances:

Year:  2018        PMID: 30548064     DOI: 10.1021/acsami.8b18288

Source DB:  PubMed          Journal:  ACS Appl Mater Interfaces        ISSN: 1944-8244            Impact factor:   9.229


  38 in total

1.  Role of LINC00152 in non-small cell lung cancer.

Authors:  Hong Yu; Shu-Bin Li
Journal:  J Zhejiang Univ Sci B       Date:  2020 Mar.       Impact factor: 3.066

Review 2.  Diagnostic, prognostic and therapeutic potential of long noncoding RNAs in cancer.

Authors:  Muhammad Babar Khawar; Syeda Eisha Hamid; Tayyba Jan; Muddasir Hassan Abbasi; Muhammad Idnan; Nadeem Sheikh
Journal:  Mol Biol Rep       Date:  2022-01-24       Impact factor: 2.316

Review 3.  Non-coding RNAs in ferroptotic cancer cell death pathway: meet the new masters.

Authors:  Mehdi Rabiee Valashedi; Chia Bamshad; Nima Najafi-Ghalehlou; Amirsadegh Nikoo; Kazuo Tomita; Yoshikazu Kuwahara; Tomoaki Sato; Amaneh Mohammadi Roushandeh; Mehryar Habibi Roudkenar
Journal:  Hum Cell       Date:  2022-04-12       Impact factor: 4.174

4.  Construction of nanocarriers based on nucleic acids and their applications in nanobiology delivery systems.

Authors:  Yingshu Guo; Xiuping Cao; Xiaofei Zheng; S K Jahir Abbas; Juan Li; Weihong Tan
Journal:  Natl Sci Rev       Date:  2022-01-17       Impact factor: 23.178

5.  Chitosan-Coated-PLGA Nanoparticles Enhance the Antitumor and Antimigration Activity of Stattic - A STAT3 Dimerization Blocker.

Authors:  Stephanie Sally Fong; Yiing Yee Foo; Wen Shang Saw; Bey Fen Leo; Yin Yin Teo; Ivy Chung; Boon Tong Goh; Misni Misran; Toyoko Imae; Chia-Ching Chang; Lip Yong Chung; Lik Voon Kiew
Journal:  Int J Nanomedicine       Date:  2022-01-11

6.  Super enhancer-LncRNA SENCR promoted cisplatin resistance and growth of NSCLC through upregulating FLI1.

Authors:  Qiang Shen; Huixin Zhou; Meijuan Zhang; Ruihao Wu; Liangxing Wang; Yumin Wang; Jie Chen
Journal:  J Clin Lab Anal       Date:  2022-05-02       Impact factor: 3.124

Review 7.  Decoding LncRNAs.

Authors:  Lidia Borkiewicz; Joanna Kalafut; Karolina Dudziak; Alicja Przybyszewska-Podstawka; Ilona Telejko
Journal:  Cancers (Basel)       Date:  2021-05-27       Impact factor: 6.639

Review 8.  Potential Therapeutic Targeting of lncRNAs in Cholesterol Homeostasis.

Authors:  Wen-Chu Ye; Shi-Feng Huang; Lian-Jie Hou; Hai-Jiao Long; Kai Yin; Ching Yuan Hu; Guo-Jun Zhao
Journal:  Front Cardiovasc Med       Date:  2021-06-10

Review 9.  Long Non-Coding RNAs in the Tumor Immune Microenvironment: Biological Properties and Therapeutic Potential.

Authors:  Ya-Nan Pi; Wen-Cai Qi; Bai-Rong Xia; Ge Lou; Wei-Lin Jin
Journal:  Front Immunol       Date:  2021-07-06       Impact factor: 8.786

Review 10.  Surface-functionalised hybrid nanoparticles for targeted treatment of cancer.

Authors:  Hasnat Tariq; Syed Ali Imran Bokhari
Journal:  IET Nanobiotechnol       Date:  2020-09       Impact factor: 1.847

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.